Hengrui Medicine
Hengrui Medicine
iangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medicine packing materials.
Hengrui Medicine, founded in April, 1997 and headquartered in Lianyungang, is an innovative pharmaceutical developer. The founder is Zhou Yunshu. Listed on the SSE on October 18, 2000, the company's major shareholders are Jiangsu Hengrui Pharmaceutical Group Co., Ltd., Tibet Dayuan Enterprise Management Co., Ltd. and Hong Kong Securities Clearing Co., Ltd.. Rivals that have direct and indirect competition with Hengrui Medicine include Harbin Pharmaceutical, Yunnan Baiyao, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
Briefing Sep 02, 2021 07:05 PM
· Healthcare
Hengrui medicine: iodofol injection passed the consistency evaluation of generic drugs
In depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Aug 20, 2021 09:48 AM
· Healthcare
Pharmaceutical and medical stocks fell sharply in early trading, and Hengrui pharmaceutical fell more than 9%
Research
Technology, Consumer Staples, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Industrials, Financials, AutomotiveTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Industrials, Financials, AutomotiveLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Insight
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Healthcare · Analysis
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Briefing Jul 20, 2021 05:50 PM
Today, the net inflow of Shanghai and Shenzhen Stock connect reached 3.065 billion, of which 572 million bought Hengrui medicine
Briefing Jul 09, 2021 04:25 PM
· Healthcare
Hengrui medicine: Zhou Yunshu resigned from the chairman, general manager and special committee of the board of directors due to physical reasons
Briefing Nov 19, 2020 09:55 AM
· Healthcare
Hengrui medicine hr091506 tablets approved for clinical use
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- More Room for the Medical Device Market to Grow in China
- Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?
- Haier Balances Smart Home Demand at Home and Overseas Trends
- TuSimple: Start with the Low-Hanging Fruit
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.